Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
WALTHAM, Mass., May 17, 2022 /PRNewswire/ -- Ardelyx Inc., (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in three posters at the 2022 Digestive Disease Week Conference (DDW 2022) to be held May 21-24, 2022, in San Diego, California and virtually.
Ardelyx Poster Presentations:
In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: IBSRELA, an Innovative Approach for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults, on May 23, 2022, from 2:30-3:15pm PT, where thought leading experts Dr. Brooks Cash and Dr. Mark Pimentel, will review the multifactorial pathophysiology of IBS-C, the novel mechanism of action of IBSRELA, and efficacy and safety data of IBSRELA from the Phase 3 clinical trial program.
Product Theater speakers: Brooks D. Cash, MD, FACG, AGAF, FASGE, Dan and Lillie Sterling Professor of Medicine, Chief, Gastroenterology, Hepatology, and Nutrition, UT Health Science Center at Houston McGovern Medical School, and Mark Pimental, MD, FRCP(C), Executive Director, Medically Associated Science and Technology (MAST) Program, Cedars- Sinai Medical Center, Los Angeles, CA.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Risk of Serious Dehydration in Pediatric Patients
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.
MOST COMMON ADVERSE REACTIONS
The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).
IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.
Please see full Prescribing Information, including Boxed Warning, for additional risk information.
About Irritable Bowel Syndrome with Constipation (IBS-C)
Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 11 million people in the US. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.
About IBSRELA for IBS-C
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-announces-additional-data-supporting-the-efficacy-and-safety-of-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-ddw-2022-301549513.html
Company Codes: NASDAQ-NMS:ARDX